Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

215.92 -3.06 (-1.40%)

Streaming Delayed Price Updated: 9:39 AM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

September 21, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary ↗

September 19, 2023

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...

Via Benzinga

Where Ligand Pharmaceuticals Stands With Analysts ↗

September 19, 2023

Via Benzinga

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

September 18, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Analyst Expectations for Ligand Pharmaceuticals's Future ↗

August 23, 2023

Via Benzinga

Recap: Ligand Pharmaceuticals Q1 Earnings ↗

May 04, 2023

Via Benzinga

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

September 01, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Second Quarter 2023 Financial Results

August 08, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 27, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Earnings Preview ↗

February 21, 2023

Via Benzinga

Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗

December 23, 2022

Via Benzinga

Ligand To Report Second Quarter 2023 Financial Results On August 8

July 25, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Why Are Novan Shares Nosediving Today? ↗

July 17, 2023

Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to

Via Benzinga

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

July 17, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

July 17, 2023

From Novan, Inc.

Via GlobeNewswire

3 Stocks That Smart Investors Should Be Flocking to Now ↗

May 30, 2023

Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors.

Via InvestorPlace

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗

May 16, 2023

Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in

Via Benzinga

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

May 16, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports First Quarter 2023 Financial Results

May 04, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

April 24, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment ↗

February 21, 2023

Via Benzinga

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

February 17, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

Ligand to Report Fourth Quarter Financial Results on February 22

February 06, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

January 06, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗

December 23, 2022

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...

Via Benzinga

Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says ↗

December 16, 2022

Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13.

Via Benzinga

Ligand Pharma Issues Mixed Guidance For FY23 ↗

December 13, 2022

At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.